Call us now:
Taikangnuo Biotech, incubated by the prestigious Tech300 Angel Fund of City University of Hong Kong, is at the forefront of innovation in the biomedical industry. Specializing in the use of artificial intelligence (AI) to analyze complex animal and human behaviours, the company focuses on addressing some of the most challenging neurological diseases, including epilepsy, Parkinson’s disease, and depression.
The cornerstone of Taikangnuo Biotech’s offerings is its Animism™ platform—a cutting-edge, multimodal AI cloud platform. Animism™ features a series of automated behavioural analysis modules designed to recognize, interpret, and evaluate various behavioural patterns related to brain diseases. The platform’s capabilities extend beyond rodents and cover pets, livestock, and human behavioural data. This versatility has allowed Taikangnuo Biotech to collaborate with leading medical institutions worldwide, enhancing preclinical pharmacological and efficacy studies.
Taikangnuo’s product suite includes specialized modules like Animism-Rodent Epilepsy 1.0, Animism-Canine Pruritus 1.0, and Animism-Pig Convulsion 1.0, each tailored for distinct research areas. These solutions empower researchers and clinicians to uncover hidden behavioural features and conduct 3D reconstructions for in-depth analysis.
Driven by a dedicated team of experts, including postdoctoral fellows and doctors from the Department of Neuroscience at the City University of Hong Kong, Taikangnuo Biotech is advancing the behavioural research field and setting a new standard in the global biomedical industry.